Abstract concept of trust in science becomes something person-to-person and concrete in the office of a pediatrician accepting of vaccine skeptical patients.
Factors include increased access to naloxone, expanded access to medications for opioid use disorder, and greater tolerance for harm reduction efforts.
TEMPO, FDA's pilot program, offers the regulators a hands-on experience with medical devices that rely on generative AI technology in real world settings.
In this edition of STAT Health Tech: What FDA's TEMPO pilot means for AI regulation, as well as patients, OpenEvidence launches new AI models, and more.
